These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 35144855)

  • 41. The effect of intensive glucose control on all-cause and cardiovascular mortality, myocardial infarction and stroke in persons with type 2 diabetes mellitus: a systematic review and meta-analysis.
    Marso SP; Kennedy KF; House JA; McGuire DK
    Diab Vasc Dis Res; 2010 Apr; 7(2):119-30. PubMed ID: 20382775
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of glucose-lowering and multifactorial interventions on cardiovascular and mortality outcomes: a meta-analysis of randomized control trials.
    Seidu S; Achana FA; Gray LJ; Davies MJ; Khunti K
    Diabet Med; 2016 Mar; 33(3):280-9. PubMed ID: 26282461
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Glucose-lowering Drugs and Hospitalization for Heart Failure: A Systematic Review and Additive-effects Network Meta-analysis With More Than 500 000 Patient-years.
    Cintra RM; Nogueira AC; Bonilha I; Luchiari BM; Coelho-Filho OR; Coelho OR; Schwartzmann P; Muscellie E; Nadruz W; Carvalho LSF; Sposito AC
    J Clin Endocrinol Metab; 2021 Sep; 106(10):3060-3067. PubMed ID: 34125217
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Incidence of Hospitalization for Heart Failure Relative to Major Atherosclerotic Events in Type 2 Diabetes: A Meta-analysis of Cardiovascular Outcomes Trials.
    Sacre JW; Magliano DJ; Shaw JE
    Diabetes Care; 2020 Oct; 43(10):2614-2623. PubMed ID: 32958618
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis.
    Fisher M; Petrie MC; Ambery PD; Donaldson J; Ye J; McMurray JJ
    Lancet Diabetes Endocrinol; 2015 Sep; 3(9):697-703. PubMed ID: 26276240
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparative cardiovascular outcomes in the era of novel anti-diabetic agents: a comprehensive network meta-analysis of 166,371 participants from 170 randomized controlled trials.
    Zhuang XD; He X; Yang DY; Guo Y; He JG; Xiao HP; Liao XX
    Cardiovasc Diabetol; 2018 Jun; 17(1):79. PubMed ID: 29871636
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Meta-Analysis of Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Cardiovascular Outcomes and All-Cause Mortality Among Patients With Type 2 Diabetes Mellitus.
    Tang H; Fang Z; Wang T; Cui W; Zhai S; Song Y
    Am J Cardiol; 2016 Dec; 118(11):1774-1780. PubMed ID: 27666177
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pioglitazone and bladder cancer risk: a systematic review and meta-analysis.
    Tang H; Shi W; Fu S; Wang T; Zhai S; Song Y; Han J
    Cancer Med; 2018 Apr; 7(4):1070-1080. PubMed ID: 29476615
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of intensive glucose lowering in treatment of type 2 diabetes mellitus on cardiovascular outcomes: A meta-analysis of data from 58,160 patients in 13 randomized controlled trials.
    Fang HJ; Zhou YH; Tian YJ; Du HY; Sun YX; Zhong LY
    Int J Cardiol; 2016 Sep; 218():50-58. PubMed ID: 27236108
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial.
    Cosentino F; Cannon CP; Cherney DZI; Masiukiewicz U; Pratley R; Dagogo-Jack S; Frederich R; Charbonnel B; Mancuso J; Shih WJ; Terra SG; Cater NB; Gantz I; McGuire DK;
    Circulation; 2020 Dec; 142(23):2205-2215. PubMed ID: 33026243
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Adding pioglitazone to insulin containing regimens in type 2 diabetes: systematic review and meta-analysis.
    Clar C; Royle P; Waugh N
    PLoS One; 2009 Jul; 4(7):e6112. PubMed ID: 19568428
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Severe Hypoglycemia and Risk of Subsequent Cardiovascular Events: Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Malik AH; Yandrapalli S; Aronow WS; Jain D; Frishman WH; Panza JA; Cooper HA
    Cardiol Rev; 2020; 28(5):244-249. PubMed ID: 31868770
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
    Kristensen SL; Rørth R; Jhund PS; Docherty KF; Sattar N; Preiss D; Køber L; Petrie MC; McMurray JJV
    Lancet Diabetes Endocrinol; 2019 Oct; 7(10):776-785. PubMed ID: 31422062
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Number needed to harm in the post-marketing safety evaluation: results for rosiglitazone and pioglitazone.
    Mendes D; Alves C; Batel-Marques F
    Pharmacoepidemiol Drug Saf; 2015 Dec; 24(12):1259-70. PubMed ID: 26376779
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials.
    Monami M; Cremasco F; Lamanna C; Colombi C; Desideri CM; Iacomelli I; Marchionni N; Mannucci E
    Exp Diabetes Res; 2011; 2011():215764. PubMed ID: 21584276
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of sodium-glucose cotransporter type 2 inhibitors on cardiovascular, renal, and safety outcomes in patients with cardiovascular disease: a meta-analysis of randomized controlled trials.
    Zheng C; Lin M; Chen Y; Xu H; Yan L; Dai H
    Cardiovasc Diabetol; 2021 Apr; 20(1):83. PubMed ID: 33888126
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Heart failure hospitalization with SGLT-2 inhibitors: a systematic review and meta-analysis of randomized controlled and observational studies.
    Singh AK; Singh R
    Expert Rev Clin Pharmacol; 2019 Apr; 12(4):299-308. PubMed ID: 30817235
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Novel antidiabetic drugs and risk of cardiovascular events in patients without baseline metformin use: a meta-analysis.
    Masson W; Lavalle-Cobo A; Lobo M; Masson G; Molinero G
    Eur J Prev Cardiol; 2021 Mar; 28(1):69-75. PubMed ID: 33606884
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The cardiovascular effects of glucagon-like peptide-1 receptor agonists: a trial sequential analysis of randomized controlled trials.
    Wu S; Sun F; Zhang Y; Yang Z; Hong T; Chen Y; Zhan S
    J Clin Pharm Ther; 2014 Feb; 39(1):7-13. PubMed ID: 24127768
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Aspirin has potential benefits for primary prevention of cardiovascular outcomes in diabetes: updated literature-based and individual participant data meta-analyses of randomized controlled trials.
    Seidu S; Kunutsor SK; Sesso HD; Gaziano JM; Buring JE; Roncaglioni MC; Khunti K
    Cardiovasc Diabetol; 2019 Jun; 18(1):70. PubMed ID: 31159806
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.